Impact of genomic alterations on outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Lu-177 radioligand therapy (RLT).
Authors: Cameron Chalker, Colin P. Bergstrom, Joseph David Allen, Burcak Yilmaz, Hong Song, Ali Raza Khaki, Alexandra Sokolova